It is not unusual for it to take at least 10 years -- sometimes even 20 -- to send a new medicine out into the world. In order to contribute to human health, we are making efforts in our research and development to deliver innovative new medicines to wherever medical care is needed in the world without delay. We are constructing the R&D pipeline with various and seamless candidate products, that can be continuously delivered to the market by realizing ever deeper levels of research and development activities.
Through efficient research and development tailored to our fields of expertise, we are aiming to produce a constant stream of new medicines. Our daily research and development efforts aim at the creation of innovative new candidate products in our research laboratories in Japan, the development of the candidate products in our international bases, and contributions to the health of people worldwide by launching them. In expanding innovative research focusing on the six areas of cardiovascular diseases, glucose metabolic disorders, infectious diseases, cancer, immunity and allergies, and bones/joint diseases, we aim to be 'First in Class’ and Best in Class' in making advances in product development in response to medical needs.
Research and Development Structure
■GEMRAD: The top decision-making system for research and development
GEMRAD (Global Executive Meeting of Research And Development) is DAIICHI SANKYO's top research and development decision-making body. Transcending systems and regional frameworks, it controls/manages global research and development from activities such as evaluating priorities, making important decisions, and allocating resources appropriately in the research and development pipeline. The members taking part in the discussions are drawn not only from the research and development division; they represent a wide range of divisions/departments, including marketing , licensing, those responsible for product portfolios, etc.
Research and Development Strategy
- ・Developing products that are best in class or first in class in response to unmet medical needs.
- ・Realizing an appropriately sized global research and development organization, balancing human resources and diversity of target areas.
- ・Realizing innovative research on a sufficient scale to deal with priority areas such as cardiovascular disease, glucose metabolic disorders, infectious diseases and cancer
- ・Ensuring sufficient human resources to develop important pipeline products without the need for tie-ups wherever possible
- ・Effective and efficient management of the development pipeline and timely decision making
- ・Maintaining excellence in global development functions by authorized development teams
- ・Being the chosen partner for licensing agreement
- ・Striving to achieve high quality in conducting every operation.
- ・Keeping in mind that there are patients constantly in need of new medicines
Research and Development Process
As a developer of new drugs, DAIICHI SANKYO is determined to contribute to treating diseases by giving the world innovative medicines.
